BACE1 and Alzheimer disease: Sha et al. 97 discovered that miR-29c-3p delivered to neurons by bone marrow MSC-EVs (BMSC-EVs) inhibits BACE1 expression and activates the Wnt/β-catenin pathway to downregulate the level of BACE1115 and thereby exert a therapeutic effect on AD.